Compare BioNano Genomics Inc (BNGO) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Newmont Corporation — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Newmont Corporation trades at $95.14 (market cap $101.15B). The key difference: Newmont Corporation is far larger — about 7662.9× BioNano Genomics Inc's market cap, and Newmont Corporation pays a 1.1% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | NEM | |
|---|---|---|
Market Cap | $13.20M | $101.15B |
Sector | Health | Basic Materials |
52-Week High | $4.92 | $131.95 |
52-Week Low | $1.09 | $57.35 |
Enterprise Value | $15.81M | $97.90B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Newmont (NEM) trades at $93.10, down 2.3% over the past day amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.08, net income margin of 33.87%, and three consecutive quarterly earnings beats. Recent news highlights Wall Street's positive valuation view despite near-term cost pressures. Cash flow trends are robust, with operating cash flow rising to $10.33 billion in 2025.
Outlook remains favorable given analyst consensus of a $140.11 price target and 75% buy ratings. Key risks include higher unit costs impacting 2026 margins and gold price volatility. The stock offers value with solid profitability and growth, though investors should monitor cost management and gold market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
